A multicentre trial with bacampicillin (Penglobe) in the treatment of respiratory tract infections in general practice.
Nine hundred and eleven patients were admitted to a multicentre trial with bacampicillin (Penglobe) in respiratory tract infections. Of these it was possible to evaluate 830 with respect to efficacy and side-effects. In most cases a dosage of 400 mg X 2 was used but in severe cases 800 mg X 2 was used. The clinical outcome was assessed as good for 79% of the patients, while 17% showed an improvement and 3% a failure. The tolerance was good with an over-all incidence of 8% side-effects, of which dyspepsia was the most common.
D000667:Ampicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001530:Belgium; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D004361:Drug Tolerance; D004415:Dyspepsia / Q000139:chemically induced; D005194:Family Practice; D006801:Humans; D010033:Otitis Media / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014069:Tonsillitis / Q000188:drug therapy
D000667:Ampicillin; C011674:bacampicillin